Common Contracts
2 similar Clinical Study Agreement contracts
CLINICAL STUDY AGREEMENT PROTOCOL: NEF-301 OLE SITE: CZ05PROF. IVAN RYCHLIK ,MD, PHD, FASN, FERA INSTITUTION: FAKULTNI NEMOCNICE KRALOVSKE VINOHRADY CALLIDITAS THERAPEUTICS AB. VERSION:#1COUNTRY: CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL:...Clinical Study Agreement • April 20th, 2021
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), dated 20th April 2021 and effective as of the day of publication in the Contracts Registry (the “Effective Date”), is entered into by and amongMedpace Clinical Research, LLC, with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA ("Medpace”), represented by ; Fakultni Nemocnice Kralovske Vinohrady , with its principal office at Srobarova 1150/50, 100 34 Praha 10, Czech Republic ("Institution”), represented by MUDr. Jan Votava, MBA, deputy for Medical and Preventive Care, representative of statutory body of FNKV, reference number KH 37/2020, cost center: 21015AndProf. Ivan Rychlik, M.D.,PhD, FASN, FERA, chief of Internal Clinic, Srobarova 1150/50, 100 34 Praha 10,Czech Republic, Date of Birth (“Investigator”).Medpace, Institution, and Investigator are sometimes collectively referred to herein each as a “Party” or collectively as the “Parties”.WHEREAS, Calliditas Therapeutics AB
CLINICAL STUDY AGREEMENT PROTOCOL: ISIS 766720-CS2 SITE: 2319PROF. MICHAL KRSEK, M.D., CSC., MBAINSTITUTION: FAKULTNI NEMOCNICE KRALOVSKE VINOHRADY IONIS PHARMACEUTICALS, INC. 19-JUNE-2018 VERSION:#1COUNTRY: CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII...Clinical Study Agreement • August 8th, 2018
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), dated 19- June-2018 and effective as of the day of publication in the Contracts Registry (the “Effective Date”), is entered into by and among Medpace Clinical Research, LLC, with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA ("Medpace”), represented by XXXXX Director, Clinical Operations; Fakultni Nemocnice Kralovske Vinohrady , with its principal office at Srobarova 1150/50, 100 34 Praha 10, Czech Republic ("Institution”), represented by XXXXX Director, reference number KH 19/2018, cost center 22055; and prof. Michal Krsek, M.D., CSc., MBA, chief of 2. interni klinika FNKV a 3. LF UK Praha, Srobarova 1150/50, 100 34 Praha 10, Czech Republic, XXXXX (“Investigator”). Medpace, Institution, and Investigator are sometimes collectively referred to herein each as a “Party” or collectively as the “Parties”. WHEREAS, Ionis Pharmaceuticals, Inc. (formerly known as Isis Pharmaceutic
